Search

Purpose: To describe published validation studies of administrative health care claims data in the Asia-Pacific region., Methods: A comprehensive literature search was conducted in PubMed for English language articles published through 31-Oct-2017 in humans from 10 Asian-Pacific countries or regions (Japan, Australia, New Zealand, China, Hong Kong, India, Singapore, South Korea, Taiwan, and Thailand) that validated claims-based diagnoses with a gold standard data source. Search terms included the: validation, validity, accuracy, sensitivity, agreement, specificity, positive predictive value, kappa, kappa coefficient, and Cohen's kappa., Results: Forty-three studies across six countries were identified: Australia (21); Japan (6); South Korea (6); Taiwan (7); Singapore (2); and New Zealand (1). Gold standard diagnoses were obtained from: medical records (18); registry data (11); self-reported questionnaires (5); and other data sources (9). Validity measures used included sensitivity, specificity, positive and negative predictive values (12); sensitivity, specificity, and positive predictive value (4); sensitivity and specificity (4); sensitivity and positive predictive value (4); and combinations of other measures (19). Validated outcomes included medical conditions (28); disease-specific comorbidities (8); death, smoking, and other (ie, injury, hospital outcome measures) (5); medication/transfusion (2). Approximately 72% of the studies were published within the last 5 years., Conclusions: Validation studies of claims data published in the English language in the Asia-Pacific region are very limited. Given the increased reliance on administrative health care databases for pharmacoepidemiology and the need for ensuring the credibility of results from such data, additional support for the conduct of validation research of claims data in the Asia-Pacific region is needed., (© 2018 John Wiley & Sons, Ltd.)

Introduction: Rapid influenza testing (RFT) allows for a rapid point-of-care diagnosis of influenza. The Quidel QuickVue Influenza A+B test (QuickVue) has a reported manufacturer's sensitivity and specificity of 73% and 96%, respectively, with nasal swabs. However, investigators have shown sensitivities ranging from 22% to 77% in community settings., Methods: The QuickVue rapid influenza test was evaluated in a population of elementary (K-5) school children, using testing in the home, as part of the Pittsburgh Influenza Prevention Project during the 2007-2008 influenza season. The QuickVue test was performed with nasal swab in full accordance with package instructions and compared with the results of nasal swab semi-quantitative RT-PCR., Results: Sensitivity of the QuickVue was found to be 27% in this sample. There was no statistically valid correlation between the semi-quantitative PCR result and the QuickVue result., Conclusions: This study is consistent with the low sensitivity of the QuickVue test also reported by others. Viral load, technique, and the use of nasal swabs were examined as contributing factors but were not found to be explanations for this result. Community testing includes patients who are on the lower spectrum of illness which would not be the case in hospital or clinic samples. This suggests that RFT is less sensitive for patients at the lower spectrum of illness, with less severe disease., (© 2010 Blackwell Publishing Ltd.)